Is Protonix affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Protonix is affected by pharmacogenetics through the CYP2C19 gene. Your genotype for this gene can change how your body processes Protonix, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Protonix

pantoprazole affected by CYP2C19

Affected by CYP2C19 · CPIC, FDA · Strong evidence

Read the full pantoprazole genetics guide →

Pantoprazole phenotype recommendations

Published guidance from CPIC and FDA on how pantoprazole should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	Your body clears the drug very quickly, so a higher dose is usually needed for the medicine to work properly.	CPIC Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. FDA Initiate therapy with recommended starting dose.	Strong
Rapid Metabolizer CYP2C19	Your body clears the drug faster than average, so sometimes a higher dose is needed, especially for certain infections.	CPIC Initiate standard starting daily dose. Consider increasing dose by 50–100% for the treatment of Helicobacter pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy. FDA Initiate therapy with recommended starting dose.	Moderate
Normal Metabolizer CYP2C19	Your body processes the drug normally, but sometimes a higher dose is needed for certain conditions.	CPIC Initiate standard starting daily dose. Consider increasing dose by 50–100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy. FDA Initiate therapy with recommended starting dose.	Moderate
Likely Intermediate Metabolizer CYP2C19	Your body holds onto the drug longer, so you may need a lower dose over long-term use to avoid side effects.	CPIC Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Optional
Intermediate Metabolizer CYP2C19	Your body holds onto the drug longer, so you may need a lower dose over long-term use to avoid side effects.	CPIC Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy. FDA Initiate therapy with recommended starting dose.	Optional
Likely Poor Metabolizer CYP2C19	Your body processes the drug slowly, so a lower dose may be needed for long-term use to prevent side effects.	CPIC Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	Moderate
Poor Metabolizer CYP2C19	Your body processes the drug slowly, so a lower dose may be needed for long-term use to prevent side effects.	CPIC Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy. FDA Consider dosage reduction in children. No dose adjustment is typically needed for adults.	Moderate
Indeterminate CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC + FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Browse the full drug-class: Proton pump inhibitors.

Related medications

Find out how your genetics affect Protonix

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.